Total Payments
$53,569
2024 Payments
$11,181
Companies
12
Transactions
55
Medicare Patients
497
Medicare Billing
$60,290
Payment Breakdown by Category
Consulting$38,408 (71.7%)
Research$7,119 (13.3%)
Travel$3,926 (7.3%)
Other$2,875 (5.4%)
Food & Beverage$1,242 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $38,408 | 13 | 71.7% |
| Unspecified | $7,119 | 6 | 13.3% |
| Travel and Lodging | $3,926 | 12 | 7.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,875 | 1 | 5.4% |
| Food and Beverage | $1,242 | 23 | 2.3% |
Payments by Type
General
$46,450
49 transactions
Research
$7,119
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $12,373 | 17 | $0 (2022) |
| ABBVIE INC. | $10,200 | 3 | $0 (2024) |
| Eli Lilly and Company | $7,475 | 2 | $0 (2020) |
| Lilly USA, LLC | $6,348 | 3 | $0 (2021) |
| Aurinia Pharma U.S., Inc. | $5,950 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $5,611 | 12 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $3,029 | 5 | $0 (2024) |
| Janssen Research & Development, LLC | $2,164 | 5 | $0 (2018) |
| Celgene Corporation | $140.00 | 1 | $0 (2018) |
| Mallinckrodt LLC | $124.78 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,181 | 5 | Aurinia Pharma U.S., Inc. ($5,848) |
| 2023 | $7,050 | 7 | AbbVie Inc. ($6,600) |
| 2022 | $4,997 | 3 | GlaxoSmithKline, LLC. ($4,895) |
| 2021 | $2,300 | 1 | Lilly USA, LLC ($2,300) |
| 2020 | $11,500 | 3 | Eli Lilly and Company ($7,475) |
| 2019 | $4,680 | 2 | GlaxoSmithKline, LLC. ($3,680) |
| 2018 | $9,413 | 31 | AstraZeneca Pharmaceuticals LP ($5,611) |
| 2017 | $2,448 | 3 | GlaxoSmithKline, LLC. ($2,300) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 11/19/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Consulting Fee | Cash or cash equivalent | $5,700.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/16/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $148.16 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 08/02/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 05/21/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $32.74 | General |
| Category: Inflammation | ||||||
| 11/13/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $93.24 | General |
| Category: Dermatology | ||||||
| 11/13/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $27.97 | General |
| Category: Dermatology | ||||||
| 11/11/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $114.16 | General |
| 05/23/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $107.52 | General |
| 05/23/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $107.52 | General |
| 03/09/2023 | AbbVie Inc. | — | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (SLEek) | ||||||
| 03/09/2023 | AbbVie Inc. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (SLEek) | ||||||
| 11/14/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $101.71 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 09/16/2022 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/15/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,370.00 | General |
| 12/03/2021 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| 09/24/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,600.00 | General |
| 08/12/2020 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| 07/22/2020 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $4,025.00 | General |
| 07/29/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,680.00 | General |
| 04/16/2019 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Immunology | ||||||
| 12/01/2018 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $54.43 | General |
| Category: IMMUNOLOGY | ||||||
| 12/01/2018 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: IMMUNOLOGY | ||||||
| 12/01/2018 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/01/2018 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $10.36 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (SLEek) | AbbVie Inc. | $6,600 | 2 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, | GlaxoSmithKline, LLC. | $518.67 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 159 | 274 | $75,208 | $15,480 |
| 2022 | 3 | 140 | 278 | $79,095 | $15,833 |
| 2021 | 4 | 128 | 204 | $87,224 | $16,889 |
| 2020 | 2 | 70 | 124 | $72,400 | $12,088 |
Total Patients
497
Total Services
880
Medicare Billing
$60,290
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 68 | 114 | $62,700 | $12,458 | 19.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 26 | $9,750 | $1,897 | 19.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 70 | 134 | $2,758 | $1,126 | 40.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 61 | 122 | $67,100 | $13,453 | 20.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 25 | $9,375 | $1,992 | 21.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 59 | 131 | $2,620 | $387.81 | 14.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 58 | 116 | $63,800 | $13,037 | 20.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 19 | 28 | $10,500 | $2,082 | 19.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $11,964 | $1,626 | 13.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 39 | 48 | $960.00 | $144.00 | 15.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 56 | 110 | $60,500 | $10,234 | 16.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $11,900 | $1,854 | 15.6% |
About Dr. Amit Saxena, MD
Dr. Amit Saxena, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2008. The National Provider Identifier (NPI) number assigned to this provider is 1568620847.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amit Saxena, MD has received a total of $53,569 in payments from pharmaceutical and medical device companies, with $11,181 received in 2024. These payments were reported across 55 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($38,408).
As a Medicare-enrolled provider, Saxena has provided services to 497 Medicare beneficiaries, totaling 880 services with total Medicare billing of $60,290. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location New York, NY
- Active Since 05/23/2008
- Last Updated 03/26/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1568620847
Products in Payments
- LUPKYNIS (Drug) $5,950
- BENLYSTA (Biological) $2,023
- ORENCIA (Biological) $1,000
- Otezla (Drug) $140.00
- ACTHAR (Biological) $124.78
- COSENTYX (Drug) $121.21
- TAVNEOS (Drug) $32.74
- BASAGLAR (Drug) $23.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M